Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT06086379 Not yet recruiting - Clinical trials for Post-Acute COVID-19 Syndrome

Cognitive Rehabilitation Therapy for COVID-19

CCT-COVID
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

Cognitive dysfunction, psychiatric symptoms, functional impairment, and disability following COVID-19 negatively impact Veterans' community functioning and quality of life, contribute to significant human suffering, and are costly to VHA. Rehabilitation is a critical priority for Veterans with long COVID. One promising treatment to improve functioning in Veterans with post-COVID-19 cognitive symptoms is Compensatory Cognitive Training (CCT). Previous studies have found that CCT is feasible, acceptable, and efficacious in Veteran populations with multiple sources of cognitive dysfunction. This randomized controlled trial aims to address important RR&D priorities by examining feasibility, acceptability, and preliminary efficacy of a COVID-19-specific rehabilitation intervention, CCT for long COVID (CCT-C) compared to a robust control condition. The proposed study has the potential to improve cognitive function, functional independence, and quality of life for Veterans with late or delayed effects of secondary conditions related to COVID-19 infections.

NCT ID: NCT06082518 Not yet recruiting - COVID-19 Clinical Trials

Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments

PCS-HBOT
Start date: December 2023
Phase: N/A
Study type: Interventional

Over 500 million people have been infected with COVID-19, and to date, more than 6 million people have died. Many individuals who have recovered from COVID-19 continue to experience symptoms even after they have been "cured" of the disease. This condition is known as post COVID-19 condition, which can have serious health consequences. A common symptom among these individuals is chronic fatigue, characterized by persistent tiredness or lack of energy. This study aims to explore a novel treatment for symptoms of post COVID-19 condition, known as hyperbaric oxygen therapy. This approach has shown promise in helping people with post COVID-19 conditions and treating some other causes of fatigue. Hyperbaric oxygen therapy involves placing patients in a small chamber where they receive high oxygen gas levels. However, this treatment is expensive and time-consuming, and it is unclear if this treatment can be effectively assessed in a large-scale research study. This small study will help us decide if conducting a large research study is feasible. The investigators aim to assess if hyperbaric oxygen therapy can improve symptoms of post COVID-19 condition, such as fatigue.

NCT ID: NCT06082258 Not yet recruiting - Clinical trials for Post-acute COVID-19 Syndrome

Education of Medical Staff to Post Acute Covid susTained sYmptoms

EMPATY
Start date: November 2023
Phase: N/A
Study type: Interventional

Evaluation of the effectiveness of a training and support intervention for general practitioners treating patients with persistent symptoms after a COVID-19 episode on the patients'quality of life at 3 months.

NCT ID: NCT06075732 Not yet recruiting - COVID-19 Clinical Trials

ACTIVATE in Public Housing

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase influenza, meningitis, pneumonia, VZV, and COVID-19 vaccine rates among under-resourced African American and Latino public housing residents in South Los Angeles.

NCT ID: NCT06068569 Not yet recruiting - COVID-19 Clinical Trials

Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers

Start date: October 2023
Phase: Phase 3
Study type: Interventional

Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic profile with participation of adult volunteers

NCT ID: NCT06068556 Not yet recruiting - COVID-19 Clinical Trials

Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)

Start date: October 2023
Phase: Phase 3
Study type: Interventional

Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac-M for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of 12-17 years old volunteers.

NCT ID: NCT06057025 Not yet recruiting - COVID-19 Clinical Trials

Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.

Start date: September 2023
Phase: Phase 3
Study type: Interventional

Safety, reactogenicity and immunogenicity study of the drug "Sputnik Lite" for the prevention of coronavirus infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of adult volunteers.

NCT ID: NCT06045338 Not yet recruiting - Long COVID Clinical Trials

Mind Body Intervention for Long COVID

Start date: October 2023
Phase: N/A
Study type: Interventional

The goal of this study is to determine if a mind-body intervention can help people suffering from symptoms associated with Long COVID. The study is a randomized trial examining the effectiveness of a mind body intervention in reducing somatic symptoms from Long COVID in participants as compared to usual care and an active control (second mind body intervention). The investigators will secondarily investigate whether the intervention alleviates individual somatic complaints and improves daily functioning, relative to usual care and the active control

NCT ID: NCT06043388 Not yet recruiting - COVID-19 Clinical Trials

Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial

Start date: September 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) after vaccination in people aged 18 and over. It is planned to screen 100 subjects who are 18 years old and above and more than 6 months since the last new coronavirus infection or new coronavirus vaccine. All subjects collected venous blood before vaccination, 14 days, 3 months, and 6 months after vaccination for immunological detection of neutralizing antibody of the new coronavirus prototype strain, Delta strain and Omicron strain (BA.4/5, XBB); All adverse events (AEs) within 30 minutes after vaccination, all AEs (including solicited and non-solicited AEs) on days 0-7, all AEs (non-solicited AEs) on days 8-30, and all AEs within 12 months after vaccination were collected. serious adverse events (SAE) and adverse events of special interest (AESI).

NCT ID: NCT06036134 Not yet recruiting - COVID-19 Pandemic Clinical Trials

Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

COVID-19 vaccines are available to children over six months, and these vaccines are powerful tools against this catastrophic pandemic. However, Hispanic/Latino children have lower COVID-19 vaccination rates than White non-Hispanic children .Our team of health communication and public health experts proposes a community-based theory-driven intervention that utilizes culturally-grounded narratives from digital storytelling to reduce Hispanic parents' COVID-19 vaccine hesitancy and increase their children's vaccine uptake.